AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 1 mg/ml administered as IV infusion Q3W for 4 administrations
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
Study NCT06150742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niyad (nafamostat mesylate)
Description: Niyad (nafamostat mesylate) lyophilized
Study NCT06150742 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% NaCl)
Description: 0.9% NaCl
Study NCT05492045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553
Description: D-1553 is a novel, targeted KRasG12C inhibitor that is being developed as a potential oral agent for advanced or metastatic solid tumors with KRasG12C mutation.
Study NCT05492045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other
Description: Standard treatment of NSCLC.
Study NCT05377723 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neodyne Device
Description: See Arm Description: Neodyne Device
Study NCT05377723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neodyne Device
Description: See Arm Description: Neodyne Device
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 6mg/ml administered as IV infusion Q3W for 4 administrations
Study NCT05120609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parkinson's Application
Description: The application delivers at-home, tailored allied health exercises (physiotherapy, speech and language therapy, and occupational therapy) for the gait, speech, and manual dexterity symptoms associated with Parkinson's disease.
Study NCT06663475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TTM-based health education videos about smoking cessation for expectant fathers
Description: Tailored for expectant fathers, this smoking cessation health education information will be developed based on transtheoretical model to motivate a quit attempt and maintain abstinence by using videos.
Study NCT06712043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Historical control group
Description: Aerobic training (see study Voet 2024, Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD)
Study NCT06712771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSA003
Description: subcutaneous injections
Study NCT06663475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care treatment
Description: general health education videos about hazards of smoking for expectant fathers in obstetric clinic
Study NCT06660121 — intervention group
Intervention type: PROCEDURE
Intervention: Electrochemotherapy with bleomycin
Description: Electrochemotherapy (ECT) with bleomycin is a localized treatment approach used for managing desmoid fibromatosis, a benign but locally aggressive tumor. This technique combines electrical pulses with the administration of bleomycin, a chemotherapeutic agent, to enhance drug uptake into tumor cells. The electrical pulses create temporary pores in the cell membranes, allowing bleomycin to enter more effectively, leading to increased cytotoxicity. ECT is typically performed on patients who have not responded to conventional therapies or for whom surgery is not feasible. ECT can lead to significant tumor shrinkage and improvement in symptoms, making it a promising option in the multidisciplinary management of desmoid fibromatosis.
Study NCT06594588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate-intensity aerobic exercise for 30-50 minutes three times a week was added to usual medical therapy
Study NCT05087342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 2.4mg
Description: The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
Study NCT05087342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be given to the control group per the schedule outlined in the armed description.
Study NCT04498767 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Each lesion may be treated with 1, 3, or 5 SBRT fractions of 16-24 Gy, 24-33 Gy or 25-40 Gy, respectively, depending on the local practice and size \& location of oligometastases. Three-fraction regimens will deliver a fraction every second day, and five-fraction regimens are delivered daily. All treatments must be completed within 2 weeks (10 working days) in order to avoid delays in starting systemic therapy.
Study NCT04498767 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Palliative RT
Description: Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions. Patients in this arm should not receive stereotactic doses or radiotherapy boosts, unless there is a clearly known clinical benefit (e.g. stereotactic radiation to a new brain metastases when all disease is controlled on systemic therapy).
Study NCT06638723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance and fall recovery training
Description: Following the video observation described in the arms, participants will undergo training to physically practice the motor tasks. The training will take place over a 2-week period encompassing 40 practice trials for each task over the training sessions. During training, the investigators will continuously monitor the changes in balance and fall recovery task performance, and will provide feedback. Participants can request to re-watch the demonstration video that they were assigned to at any time.
Study NCT06638580 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Periodontal Measurements (plaque index, gingival index, bleeding index, clinical attachment level), Optical Coherence Tomographic Measurements, Serum IL1-β, TNF-α, IL-10, TAS, TOS, OSİ levels
Description: Probing pocket depth (PPD) was measured as the distance between the deepest point of the sulcus (or pocket) and the gingival margin, and clinical attachment level (CAL) was measured as the distance between the base of the pocket and the cementoenamel junction. PPD and CAL were measured at six different points (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, and disto-lingual) in each tooth, and other index scores were taken at four different points (mesial, distal, vestibular and palatinal).~Serum IL1-β, TNF-α, and IL-10 levels were measured via immunosorbent assay method using human-specific kits according to the kit manufacturer's instructions.~Serum total antioxidant status (TAS) and total oxidant status (TOS) levels were mea-sured by a spectrophotometric method using specific kits.~Retinal and choroidal imaging and measurements were performed with optical coherence tomography (SS-OCT) with swept-source (SS) technology and non-invasive OCT angiography.
Study NCT06636760 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains the non-active carrier of herbal combination that has no pharmacological activity.
Study NCT06636760 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal compound
Description: The herbal combination is made up of various medicinal plants and possesses immunomodulator properties. It comprises Phyllanthus niruri, Andrographis paniculata, and Glycyrrhiza glabra, along with Anacardium occidentale leaf and Zingiber officinale rhizome, all recognized for their immunomodulatory properties.
Study NCT06640556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: watching animation show
Description: The intervention group will watch the animation titled 'A Green Future with the Hand of a Midwife' on days 7, 21, and 30 to mothers who have just given birth, and the scale will be evaluated on three separate days in total.
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone 600 mg
Description: Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized Progesterone 600 mg
Description: Vaginal supplementary micronized progesterone will be given after postovulatory administration of the progesterone receptor antagonist mifepristone. Administration from LH+3 to LH+5 (LH peak=LH+0); 200 mg 3 times per day.
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone 200 mg
Description: Post ovulatory single oral administration (LH+2, LH peak=LH+0)
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mifepristone 200 mg
Description: Post ovulatory single oral administration (LH+2, LH peak=LH+0)
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo Tablet
Description: Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo Tablet
Description: Oral placebo tablet containing brewer yeast, cellulose, stearic acid, silica, magnesium stearate
Study NCT06616077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal
Description: Cocoa butter
Study NCT06678321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobil game
Description: Participants in the intervention group will be asked to play the game and complete all parts.
Study NCT06679634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoplaque also referred to as Episcleral Topotecan
Description: Sustained Release Episcleral Topotecan
Study NCT06677983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bioflex Crowns
Description: A preformed crown of similar size will be selected. Tooth preparation will be done using a tapered diamond bur to reduce the occlusal surface, including the central groove, by 1-1.5 mm. The proximal surfaces will be prepared by approximately 0.5 mm to clear the contact area.
Study NCT06677983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: An appropriately sized preformed stainless-steel crown will be selected. Tooth preparation will involve using a tapered bur ) to reduce the occlusal surface by 1 to 1.5 mm, with interproximal reduction made on the mesial and distal sides. The selected crown size will be checked, and a trial fit will be conducted prior to cementation. Crimping pliers will be used, and the crown will be cemented with Type 1 glass ionomer cement. Any excess cement will be removed, and proper occlusion will be verified.
Study NCT06642805 — intervention group
Intervention type: PROCEDURE
Intervention: duodenal atresia
Description: surgery for duodenal atresia
Study NCT05120609 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Digital Placebo Application
Description: The application is designed to provide a method of capturing outcome measures without providing access to the therapy exercises.
Study NCT06712771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections
Study NCT06708429 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
Description: A combination of blood-based, mucosal-based, and hair-based analyses that evaluate the presence and the expression of:~* a set of microRNAs (blood)~* antibodies anti-frame shift peptides (blood)~* mucosal-resident bacteria (healthy mucosa and cancer)~* environmental exposure to potential carcinogens (hair matrix)
Study NCT06561126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory, Learning and Action Based Intervention
Description: The total number of participants exposed to the intervention (adapted from the DMagic trial in Bangladesh) will be determined based on random selection from the community. A PLA-based intervention would be carried out to prepare the Diabetes Mellitus type II patients. The intervention would be carried out for a tentative time of 2 to 3 hours to educate the type II diabetes mellitus. The study participants would be evaluated after 18 months of the intervention. A structured, validated and literature-based assessment checklist will be devised to assess the effectiveness and feasibility of the intervention.
Study NCT05812170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational online session about PF
Description: The educational online session will last 90 minutes, as follows: 10 minutes of contextualization, 40 minutes of practical content about pelvic floor consciousness and 40 of theoretical content (anatomy and practices related to PFD).
Study NCT05752032 — intervention group
Intervention type: GENETIC
Intervention: ICM-203
Description: Long term follow-up
Study NCT05752032 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Long term follow-up
Study NCT06679569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium 0.2 mg/kg/hr continuous infusion
Description: To maintain Train-of-four count 1 to 3 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.2 mg/kg/hr to achieve and sustain moderate neuromuscular blockade.
Study NCT06567262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM metallic removable partial denture
Description: Make digital scans using an intraoral scanning device. Scan the maxillary (antagonistic scan) and mandibular (pre-preparation scan) arches, as well as an initial digital record of the inter-occlusal relation (occlusal scan).~Analyse the digital cast using CAD software. Primary electronic surveying will be carried out to ensure if the tooth preparations will be needed.~Make a definitive intraoral scan only of the prepared teeth and record the maxillary-mandibular relationship.~The virtual cast is digitally surveyed and the design of the framework is done using computer software. The wax pattern 3D framework information will be converted into a standard tessellation language (STL) file and transfer to a rapid prototyping (RP) system to be printed and finally cast using the conventional technique to produce RPD framework.
Study NCT06567262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional metallic removable partial denture
Description: Primary impressions will be taken, the impressions will be poured to construct a study casts.~Maxillary Face-bow record and diagnostic bite will be taken. The study casts will be mounted on semi adjustable articulator to check inter-arch space.~Surveying of the study cast will be done. Required mouth preparation will be carried out then secondary impression will be taken using special tray.~Secondary impression will be poured to obtain master cast which will be surveyed to confirm proper mouth preparation, blocked out and then wax pattern will be designed and constructed.~A metallic framework will be obtained using the conventional lost wax technique and casting.~Intraoral try in of the framework will be done followed by bite registration record.~The next step will be teeth setting and try in. Heat cured acrylic resin denture base will be processed, finished and polished conventionally.
Study NCT05644132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InDx Implant for the carpometacarpal joint
Description: Treatment of thumb base joint arthritis with the InDx Implant
Study NCT06039761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digestive or gynecological surgery by laparoscopy
Description: Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
Study NCT06039761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digestive or gynecological surgery by laparoscopy
Description: Digestive or gynecological surgery by laparoscopy with a Transversus abdominis plane block before the incision and systematic standardized multimodal analgesia
Study NCT06679569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium 0.6 mg/kg/hr continuous infusion
Description: To maintain Train-of-four count 0 during surgery: Administration of continuous infusion of rocuronium at a rate of 0.6 mg/kg/hr to achieve and sustain deep neuromuscular blockade.
Study NCT06679244 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic proximal gastrectomy with Hao's esophagogastrostomy by fissure technique
Description: This is an innovative surgical method applied in proximal gastrectomy. By adding anti reflux structures such as false gastric fundus and false cardia on the basis of esophageal residual gastric anastomosis, the goal of anti reflux is achieved, while maintaining normal physiological channels and fully utilizing residual gastric function, reducing the difficulty of proximal gastrectomy surgery
Study NCT06679244 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Totally laparoscopic proximal gastrectomy with double-tract reconstruction
Description: This is a traditional surgical method that has been widely used in proximal gastrectomy. After disconnecting the proximal stomach, performing Roux-en-Y anastomosis of the esophagus and jejunum firstly, followed by lateral anastomosis of the residual stomach and jejunum. Previous studies have confirmed its safety and effectiveness, but there are also issues of gastric channel disuse and high missed detection rate of residual stomach.
Study NCT05212038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iliopsoas plane block group
Description: Ultrasound-guided iliopsoas plane block with 0.75% ropivacaine 10 ml and epinephrine 0.05 ml (1:200,000) 10 ml
Study NCT05212038 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham block group
Description: Ultrasound-guided iliopsoas plane block with normal saline 10 ml
Study NCT05793632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
Study NCT05491850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Physical Activity for Peripheral Diabetic Neuropathy
Description: Moderate physical activity can increase movement and heart rate are particularly important for people suffering with peripheral neuropathy. Physical activity can improve blood circulation, which strengthens nerve tissues by increasing the flow of oxygen.
Study NCT04954989 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
Study NCT04954989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) of the experimental drug should be administered subcutaneously
Study NCT04954989 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
Study NCT04954989 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active comparator Erythropoietin subcutaneous injection single dose of 4,000 IU
Description: Recombinant Human Erythropoietin: single dose of 4,000 IU (syringe filled with 0.4 mL with 4,000 IU) should be administered subcutaneously
Study NCT05881291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: induction of anesthesia：group ciprofol received an IV injection of ciprofol at a dose of 0.2-0.4 mg/kg, and administration time of 30 s.When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia: group ciprofol received an IV infusion of ciprofol 0.8-2.4 mg·kg-1·h-1.
Study NCT05881291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: induction of anesthesia：group propofol received an IV injection of propofol at a dose of 1.0-2.0 mg/kg, and administration time of 30 s. When the eyelash reflex disappeared and the BIS value was ≤60 administration was stopped, followed by an IV injection of alfentanil 30 μg/kg and rocuronium 0.6 mg/kg.~Maintenance of anesthesia:group propofol received an IV infusion of propofol 4-6 mg·kg-1·h-1.
Study NCT05693766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000 mg taken by mouth twice daily for 7 days on, 7 days off
Study NCT05693766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine-therapy
Description: Endocrine therapy administered
Study NCT05693766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MammoPrint ® and BluePrint assays
Description: Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
Study NCT05693766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MammoPrint ® and BluePrint assays
Description: Archival tissue will be analyzed using the MammoPrint ® and BluePrint assays
Study NCT05226598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/vial administered as IV infusion Days 1, 8, and 15 of each 21-day cycle for 4 administrations